The BCAT1 CXXC motif and oncogenesis in acute myeloid leukaemia

About the Project

The BCAT1 gene is implicated in the pathogenesis of many cancer types, including acute myeloid leukaemia (AML)^1–4. Recently, our group identified a novel antioxidant role for BCAT1 in AML cells⁵. We demonstrated that BCAT1 was able to protect AML cells from damaging effects mediated by oxidative stress, keeping the AML cells in a tumorigenic state.

Oxidative stress is known to interact with numerous signalling processes that promote tumorigenesis in AML^6,7, however the role BCAT1 plays in these wider signalling processes remains unknown. Given that BCAT1 represents a potential target for treating AML, this project aims to understand these processes, and how they may be targeted therapeutically.

This project incorporates numerous methodologies, including, human cell culture, multiparameter flow cytometry, fluorescence microscopy, toxicology screening assays and western blotting. Applications from candidates with knowledge or previous experience in these techniques are encouraged.

• Director of Studies: Dr Steven Coles
• Supervisors: Dr Amy Cherry, Dr Joanne Whittaker
• Research Group: Worcester Biomedical Research Group (WBRG)

Additional costs

Given that this is a laboratory-based project, bench fees will apply to cover the procurement of reagents essential to delivering the research objectives. This will include cell culture media and antibodies.

Application Process

To begin the application process please go to: https://www.worc.ac.uk/research/research-degrees/applying-for-a-phd/.

The Interview

All successful applicants will be offered an interview with the proposed Supervisory Team. You will be contacted by a member of the Doctoral School Team to find a suitable date. Interviews can be conducted in person or over Microsoft Teams.